Search Within

Jose T Baselga

Formats
  1. Meeting Abstract (241)
  2. Journal Article (233)
  3. Conference Paper (4)
  4. Research Letter (3)
  5. Book Section (2)
  6. Review (1)
Groups
  1. Department of Medicine (197)
  2. Solid Tumor Oncology Division (192)
  3. Breast Medicine Service (149)
  4. GSK Faculty (128)
  5. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (108)
  6. Human Oncology and Pathogenesis Program (97)

More Groups

People
  1. David Hyman (68)
  2. Maurizio Scaltriti (63)
  3. Clifford Hudis (57)
  4. Michael Berger (56)
  5. Larry Norton (51)
  6. Sarat Chandarlapaty (48)

More People

Years
  1. 2021 (5)
  2. 2020 (11)
  3. 2019 (25)
  4. 2018 (58)
  5. 2017 (68)
  6. 2016 (67)

More Years

Publications
  1. Cancer Research (109)
  2. Journal of Clinical Oncology (92)
  3. Annals of Oncology (29)
  4. Clinical Cancer Research (29)
  5. European Journal of Cancer (25)
  6. Cancer Discovery (13)

More Publications

Publishers
  1. American Association for Cancer Research (163)
  2. American Society of Clinical Oncology (97)
  3. Oxford University Press (41)
  4. Elsevier Inc. (39)
  5. Nature Publishing Group (30)
  6. Springer (16)

More Publishers

Results (484)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC)
    Meeting Abstract

    Shah, P. D.; Chandarlapaty, S.; Dickler, M. N.; Ulaner, G.; Zamora, S. J.; Sterlin, V.; Iasonos, A.; Coughlin, C. M.; Morozov, A.; Ero, J.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • The clinical utility of ERBB2 amplification detection in breast carcinoma using a 341 gene hybrid capture-based next generation sequencing (NGS) assay: Comparison with standard immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) assays
    Meeting Abstract

    Ross, D. S.; Zehir, A.; Cheng, D. T.; Nafa, K.; Jour, G.; Razavi, P.; Hyman, D. M.; Baselga, J.; Berger, M. F.; Ladanyi, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Is next generation sequencing (NGS) ready for routine clinical practice in gliomas? Results of a prospective study utilizing the MSK-IMPACT assay
    Meeting Abstract

    Omuro, A. M. P.; Zehir, A.; Cheng, D. T.; Berger, M. F.; Hyman, D. M.; Solit, D. B.; Baselga, J.; Ladanyi, M.; Arcila, M. E.; Hameed, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • FAIRLANE: A phase II randomized, double-blind, study of the Akt inhibitor ipatasertib (Ipat, GDC-0068) in combination with paclitaxel (Pac) as neoadjuvant treatment for early stage triple-negative breast cancer (TNBC)
    Meeting Abstract

    Oliveira, M.; Saura, C.; Gonzalez Martin, A.; Andersen, J. C.; Fisher, J. G.; Calvo, I.; Ciruelos, E.; Gil, M.; de la Pena, L.; Llobet-Canela, M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Correlation of PIK3CA mutation with pathological complete response in primary HER2-positive breast cancer: Combined analysis of 967 patients from three prospective clinical trials
    Meeting Abstract

    Loibl, S.; Majewski, I.; Guarneri, V.; Nekljudova, V.; Holmes, E. M.; Bria, E.; Denkert, C.; Eidtmann, H.; Sotiriou, C.; Loi, S.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • LORELEI: A phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer
    Meeting Abstract

    de Azambuja, E.; Saura, C.; Oliveira, M.; Dubsky, P. C.; Zardavas, D.; Fesl, C.; Bardia, A.; Lin, R.; Fredrickson, J. O.; Parmar, H.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • SANDPIPER: Phase III study of the PI3-kinase (PI3K) inhibitor taselisib (GDC-0032) plus fulvestrant in patients (pts) with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (BC) enriched for pts with PIK3CA mutant tumors
    Meeting Abstract

    Baselga, J.; Cortes, J.; De Laurentiis, M.; Dieras, V.; Harbeck, N.; Im, Y. H.; Jacot, W.; Krop, I. E.; Verma, S.; Wilson, T. R.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Trastuzumab and pertuzumab-based versus other therapy as second-line therapy in HER2-positive metastatic breast cancer: A retrospective study from single center
    Meeting Abstract

    Fontes Santos De Teive Argolo, D.; Smyth, L. M.; Iyengar, N. M.; Patil, S.; Norton, L.; Baselga, J.; Hudis, C. A.; Dang, C. T.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
    Journal Article

    Nuciforo, P. G.; Aura, C.; Holmes, E.; Prudkin, L.; Jimenez, J.; Martinez, P.; Ameels, H.; de la Pena, L.; Ellis, C.; Eidtmann, H.; more...
    Annals of Oncology (2015)

    Fulltext@MSK | Save
  • Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations
    Journal Article

    Hyman, D. M.; Puzanov, I.; Subbiah, V.; Faris, J. E.; Chau, I.; Blay, J. Y.; Wolf, J.; Raje, N. S.; Diamond, E. L.; Hollebecque, A.; more...
    New England Journal of Medicine (2015)

    Fulltext@MSK | Save